indazoles has been researched along with fluorouracil in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (75.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hahn, GM; Ning, SC | 1 |
| Ballatore, P; Calabresi, F; Calabró, A; Curcio, CG; Di Lauro, L; Di Palma, M; Foggi, CM; Giannarelli, D; Marolla, P; Paoletti, G | 1 |
| Nardini, S | 1 |
| Astone, A; Barone, C; Cassano, A; Colloca, G; Corsi, DC; Fontana, T; Landriscina, M; Noviello, MR; Pozzo, C | 1 |
| Abhyankar, V; Burgess, RE; Chen, Y; Infante, J; Kim, S; Robles, RL; Sharma, S; Tarazi, J; Tortorici, M; Trowbridge, RC | 1 |
| Greten, TF; Manns, MP; Plentz, RR | 1 |
| He, B; Xie, F; Zhao, J; Zhao, T | 1 |
| Chen, Y; Cohen, RB; Herbst, RS; Kim, S; Kozloff, MF; Martin, LP; Olszanski, AJ; Rado, T; Rosbrook, B; Samuel, TA; Starr, A; Tarazi, J; Tortorici, M | 1 |
| Adams, LM; Botbyl, J; Brady, J; Chau, I; Corrie, P; Digumarti, R; Laubscher, KH; Mallath, M; Midgley, RS | 1 |
| Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kern, C; Nagel, D; Stieber, P; Wittwer, C | 1 |
| Cartwright, TH; Cescon, TP; Cohn, AL; Edenfield, WJ; Hamm, JT; Infante, JR; Kim, S; Malik, IA; McGee, PJ; Rado, TA; Reid, TR; Richards, DA; Rosbrook, B; Tarazi, J | 1 |
| Agarwal, KL; Bakris, GL; Bhatta, SS; Cohen, EE; Karrison, T; Maitland, ML; Ratain, MJ; Seiwert, TY; Sit, L; Vokes, EE; Wroblewski, KE | 1 |
| Barone, C; Bendell, JC; Bloom, J; Kim, JG; Kim, S; Pastorelli, D; Pericay, C; Ricart, AD; Rosbrook, B; Sobrero, AF; Swieboda-Sadlej, A; Tarazi, J; Tournigand, C; Wainberg, ZA | 1 |
| Bendell, JC; Burris, HA; Hoh, CK; Infante, JR; Kim, S; Reid, TR; Rosbrook, B; Tarazi, J | 1 |
| Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ | 1 |
| Gao, J; Ge, S; He, Q; Li, Y; Peng, Z; Shen, L; Wang, T | 1 |
| Berlin, J; Cainap, C; Carlson, DM; Fischer, J; Goldberg, RM; Gorbunova, V; Karapetis, CS; Kim, TW; McKee, MD; O'Neil, BH; Qian, J; Qin, Q; Ricker, JL; Van Cutsem, E | 1 |
| Bhatt, K; Bury, MJ; Fehrenbacher, L; Flynn, PJ; Geyer, CE; Goel, R; Jacobs, SA; Johannes, H; Julian, TB; Mamounas, EP; Provencher, L; Rastogi, P; Robidoux, A; Stella, PJ; Swain, SM; Tan, AR; Thirlwell, MP; Wolmark, N | 1 |
| Chen, J; Chen, Z; Guo, J; Liu, M; Pang, X; Wang, J | 1 |
| Al-Batran, SE; Bartels, P; Breithaupt, K; Gläser, D; Hinke, A; Högner, A; Homann, N; Lorenz, M; Malfertheiner, P; Siveke, JT; Stein, A; Tamm, I; Thuss-Patience, P; Vogel, A | 1 |
3 review(s) available for indazoles and fluorouracil
| Article | Year |
|---|---|
Non small cell lung cancer and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Fluorouracil; Humans; Indazoles; Lomustine; Lung Neoplasms; Methotrexate; Neoplasm Staging; Treatment Outcome | 1994 |
Molecular therapy of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
12 trial(s) available for indazoles and fluorouracil
| Article | Year |
|---|---|
Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Indazoles; Middle Aged; Prospective Studies; Remission Induction; Time Factors | 1991 |
Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or a cisplatin-based regimen: two parallel randomized phase II studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Indazoles; Leucovorin; Male; Middle Aged; Prognosis; Quality of Life; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 1998 |
A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Treatment Outcome | 2010 |
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Taxoids; Treatment Outcome | 2012 |
An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Indazoles; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Keratin-19; Middle Aged; Multivariate Analysis; Oximes; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Piperazines; Prospective Studies; Quinazolines; Sirolimus; Sulfonamides; Survival Rate | 2013 |
Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Infusions, Intravenous; Injections, Intravenous; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Treatment Outcome | 2013 |
Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Young Adult | 2013 |
Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Female; Fluorodeoxyglucose F18; Fluorouracil; Gastrointestinal Neoplasms; Humans; Imidazoles; Indazoles; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Positron-Emission Tomography; Protein Kinase Inhibitors; Radiopharmaceuticals; Withholding Treatment | 2014 |
Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Hypothyroidism; Indazoles; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Phenylurea Compounds; Survival Rate; Thrombocytopenia; Young Adult | 2014 |
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Indazoles; Lymph Nodes; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pyrimidines; Receptor, ErbB-2; Sulfonamides | 2015 |
Pazopanib with 5-FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase-II study-The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO-STO-0510.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Esophagogastric Junction; Female; Fluorouracil; Humans; Indazoles; Male; Middle Aged; Oxaliplatin; Pyrimidines; Stomach Neoplasms; Sulfonamides | 2022 |
5 other study(ies) available for indazoles and fluorouracil
| Article | Year |
|---|---|
Combination therapy: lonidamine, hyperthermia, and chemotherapy against the RIF-1 tumor in vivo.
Topics: Animals; Antineoplastic Agents; Bleomycin; Carmustine; Combined Modality Therapy; Fibrosarcoma; Fluorouracil; Hyperthermia, Induced; Indazoles; Male; Mice; Mice, Inbred C3H; Neoplasms, Radiation-Induced; Sarcoma, Experimental | 1991 |
[Therapeutic effect of axitinib and 5-FU in nude mice bearing human colon cancer xenograft].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Cell Line, Tumor; Colonic Neoplasms; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Xenograft Model Antitumor Assays | 2012 |
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.
Topics: Axitinib; Blood Pressure; Clinical Trials as Topic; Combined Modality Therapy; Erythrocyte Count; Erythropoiesis; Erythropoietin; Fluorouracil; Humans; Imidazoles; Indazoles; Neoplasms; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2013 |
Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Axitinib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Cisplatin; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Linifanib (ABT-869) Potentiates the Efficacy of Chemotherapeutic Agents through the Suppression of Receptor Tyrosine Kinase-Mediated AKT/mTOR Signaling Pathways in Gastric Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Down-Regulation; Drug Synergism; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Mice; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Receptor Protein-Tyrosine Kinases; Signal Transduction; Stomach Neoplasms; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |